Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
NGNE Neurogene PE ratio, current and historical analysis
- Stocks
- Healthcare
- NASDAQ: NGNE
- PE Ratio
The current PE ratio of NGNE cannot be calculated, as the latest EPS of -$4.35 is negative.
NGNE PE ratio history
How has NGNE's PE ratio performed in the past
Today
N/A
Average
N/A
Median
N/A
Minimum
N/A
Maximum
N/A
Neurogene PE ratio by year
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2024 | N/A | N/A | $22.86 | -$4.28 |
| 2023 | N/A | N/A | $19.38 | -$117.28 |
| 2022 | N/A | N/A | $10.18 | -$139.88 |
| 2021 | N/A | N/A | $96.4 | -$22 |
| 2020 | N/A | N/A | $282 | -$12.8 |
| 2019 | N/A | N/A | $246.4 | -$51.4 |
| 2018 | N/A | N/A | $43.2 | -$26.8 |
| 2017 | N/A | N/A | $235.2 | -$42.8 |
| 2016 | N/A | N/A | $330.2 | -$39.2 |
| 2015 | N/A | N/A | $249.6 | -$34.6 |
| 2014 | N/A | N/A | $150 | -$55 |
| 2013 | N/A | N/A | N/A | -$990.4 |
| 2012 | N/A | N/A | N/A | -$804.6 |
Neurogene PE ratio by quarter (TTM)
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Mar 2025 | N/A | N/A | $11.71 | -$4.35 |
| Dec 2024 | N/A | N/A | $22.86 | -$4.28 |
| Sep 2024 | N/A | N/A | $41.96 | -$32.9 |
| Jun 2024 | N/A | N/A | $36.39 | -$64.38 |
| Mar 2024 | N/A | N/A | $50.9 | -$89.97 |
| Dec 2023 | N/A | N/A | $19.38 | -$117.28 |
| Sep 2023 | N/A | N/A | $15.8 | -$211.55 |
| Jun 2023 | N/A | N/A | $16.6 | -$183.6 |
| Mar 2023 | N/A | N/A | $14 | -$162.52 |
| Dec 2022 | N/A | N/A | $10.18 | -$139.88 |
| Sep 2022 | N/A | N/A | $12.8 | -$21.32 |
| Jun 2022 | N/A | N/A | $20.6 | -$22.2 |
| Mar 2022 | N/A | N/A | $37.6 | -$22 |
| Dec 2021 | N/A | N/A | $96.4 | -$22 |
| Sep 2021 | N/A | N/A | $144.6 | -$21 |
NGNE Price vs fair value
How does NGNE's price compare to its estimated fair value based on its growth
NGNE average PE ratio chart
What is the average PE ratio of NGNE for the past years
3-year avg
N/A
5-year avg
N/A
10-year avg
N/A
15-year avg
N/A
NGNE PE vs peers
What is NGNE's PE ratio compared to its peers
| Stock name | PE ratio | Market cap |
|---|---|---|
| OLMA Olema Pharmaceuticals Inc | N/A | $298.32M |
| OMER Omeros Corp | N/A | $210.93M |
| VIVS VivoSim Labs Inc. | N/A | $2.68M |
| ORIC Oric Pharmaceuticals Inc | N/A | $670.36M |
| ORMP Oramed Pharmaceuticals Inc | N/A | $88.24M |
| NGNE Neurogene Inc | N/A | $345.43M |
Frequently asked questions
What is Neurogene's PE ratio?
The current price to earnings ratio of NGNE cannot be determined, as its EPS of -$4.35 is negative.
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.